955360-42-6

Basic information

• Product Name: 4-[(4-chlorophenyl)methyl]-2-[(2R)-2-pyrrolidinylmethyl]pyrido[3,4-d]pyridazin-1(2H)-one
• Synonyms: 4-[(4-chlorophenyl)methyl]-2-[(2R)-2-pyrrolidinylmethyl]pyrido[3,4-d]pyridazin-1(2H)-one
• CAS NO: 955360-42-6
• Molecular Weight: 354.839
• Mol File: 955360-42-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-[(4-chlorophenyl)methyl]-2-[(2R)-2-pyrrolidinylmethyl]pyrido[3,4-d]pyridazin-1(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(4-chlorophenyl)methyl]-2-[(2R)-2-pyrrolidinylmethyl]pyrido[3,4-d]pyridazin-1(2H)-one(955360-42-6)
• EPA Substance Registry System: 4-[(4-chlorophenyl)methyl]-2-[(2R)-2-pyrrolidinylmethyl]pyrido[3,4-d]pyridazin-1(2H)-one(955360-42-6)

Safety Data

• Hazardous Substances Data: 955360-42-6(Hazardous Substances Data)

Upstream product

• 33155-59-8 tert-butyl 2-(4-chlorophenyl)acetate 
• 1878-66-6 4-chlorophenylacetic Acid 
• 955360-41-5 4-[(4-chlorophenyl)methyl]pyrido[3,4-d]pyridazin-1(2H)-one 
• 955360-40-4 methyl 3-[(4-chlorophenyl)acetyl]-4-pyridinecarboxylate 
• 955360-39-1 methyl 3-{2-(4-chlorophenyl)-3-[(1,1-dimethylethyl)oxy]-3-oxopropanoyl}-4-pyridinecarboxylate 
• 24202-74-2 4-(methoxycarbonyl)nicotinic acid 
• 4664-08-8 cinchomeronic anhydride 
• 1141946-37-3 C₂₄H₂₇ClN₄O₃ 

Downstream Products

• 1401246-57-8 CH₂O₂*C₂₃H₂₇ClN₄O 
• 1401246-55-6 C₂₀H₂₁ClN₄O 
• 1401246-58-9 C₂₂H₂₅ClN₄O₂ 
• 1141946-09-9 4-[(4-chlorophenyl)methyl]-2-({(2R)-1-[2-(ethylsulfonyl)ethyl]-2-pyrrolidinyl}methyl)pyrido[3,4-d]pyridazin-1(2H)-one 
• 1035042-21-7 2-[2-((2R)-2-{[4-[(4-chlorophenyl)methyl]-1-oxopyrido[3,4-d]pyridazin-2(1H)-yl]methyl}-1-pyrrolidinyl)ethyl]-1H-isoindole-1,3(2H)-dione 

Relevant articles and documents

Synthesis and pharmacological investigation of azaphthalazinone human histamine H1 receptor antagonists

5-Aza, 6-aza, 7-aza and 8-aza-phthalazinone, and 5,8-diazaphthalazinone templates were synthesised by stereoselective routes starting from the appropriate pyridine/pyrazine dicarboxylic acids by activation with CDI, reaction with 4-chlorophenyl acetate ester enolate to give a β-ketoester, which was hydrolysed, and decarboxylated. The resulting ketone was condensed with hydrazine to form the azaphthalazinone core. The azaphthalazinone cores were alkylated with N-Boc-D-prolinol at N-2 by Mitsunobu reaction, de-protected, and then alkylated at the pyrrolidine nitrogen to provide the target H 1 receptor antagonists. All four mono-azaphthalazinone series had higher affinity (pKi) for the human H1 receptor than azelastine, but were not as potent as the parent non-aza phthalazinone. The 5,8-diazaphthalazinone was equipotent with azelastine. The least potent series were the 7-azaphthalazinones, whereas the 5-azaphthalazinones were the most lipophilic. The more hydrophilic series were the 8-aza series. Replacement of the N-methyl substituent on the pyrrolidine with the n-butyl group caused an increase in potency (pA2) and a corresponding increase in lipophilicity. Introduction of a β-ether oxygen in the n-butyl analogues (2-methoxyethyl group) decreased the H1 pA2 slightly, and increased the selectivity against hERG. The duration of action in vitro was longer in the 6-azaphthalazinone series. The more potent and selective 6-azaphthalazinone core was used to append an H3 receptor antagonist fragment, and to convert the series into the long acting single-ligand, dual H1 H3 receptor antagonist 44. The pharmacological profile of 44 was very similar to our intranasal clinical candidate 1.

2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS

The present invention relates to compounds of formula (I), and salts thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various disorders, such as allergic rhinitis.